Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fam3b
- Development stage
- Preclinical
- Lead developer
- Forcefield Therapeutics
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Fam3b is a cardioprotective therapeutic candidate being developed by Forcefield Therapeutics for the treatment of acute myocardial infarction (AMI) and the prevention of subsequent heart failure. Identified through the FunSel screening platform in collaboration with King's College London, Fam3b is a secreted protein that protects cardiomyocytes from death following ischemic injury. Its mechanism of action involves the activation of autophagy, prevention of cardiomyocyte apoptosis, and inhibition of cardiac fibrosis through the suppression of TGF-beta signaling. The development program encompasses two modalities: a recombinant protein therapeutic intended for acute administration immediately following a heart attack, and an alternative AAV-mediated gene therapy approach being explored in partnership with Freeline Therapeutics.
- Other names
- FAM3 metabolism regulating signaling molecule BFAM-3 metabolism regulating signaling molecule BFAM 3 metabolism regulating signaling molecule BFAM3BFAM-3BFAM 3B
02
Targets
FGFR (FGFR family)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on Fam3b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fam3b.